Menu

Search

  |   Business

Menu

  |   Business

Search

MyoKardia to Present at 36th Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 03, 2018 -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced that Tassos Gianakakos, Chief Executive Officer, is scheduled to present at the 36th Annual J.P. Morgan Healthcare Conference on Tuesday, January 9th, 2018, at 2:30 p.m. PT (5:30 p.m. ET) in San Francisco.

A webcast of the presentation will be available by visiting the Investors section of MyoKardia’s website at http://investors.myokardia.com. A replay of the webcast will be available on the MyoKardia website for 90 days following the conference.

About MyoKardia

MyoKardia is a clinical-stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and rare cardiovascular diseases.  MyoKardia’s initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction.  MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy—hypertrophic cardiomyopathy (HCM), and dilated cardiomyopathy (DCM). MyoKardia’s most advanced product candidate is mavacamten (formerly MYK-461), a novel, oral, allosteric modulator of cardiac myosin that has been shown to reduce hypercontractility in early clinical studies and is currently being studied in the Phase 2 PIONEER-HCM clinical trial.  MYK-491, MyoKardia’s second product candidate, is designed to increase the overall extent of the heart’s contraction in DCM patients by increasing cardiac contractility. MyoKardia is currently evaluating MYK-491 in a Phase 1 study in healthy volunteers.  A cornerstone of the MyoKardia platform is the Sarcomeric Human Cardiomyopathy Registry (SHaRe), a multi-center, international repository of clinical and laboratory data on individuals and families with genetic heart disease, which MyoKardia helped form in 2014. MyoKardia’s mission is to change the world for patients with serious cardiovascular disease through bold and innovative science.

Contacts

Beth DelGiacco (Investors)
Stern Investor Relations, Inc.
212-362-1200
[email protected]

Steven Cooper (Media) 
Edelman
415-486-3264
[email protected]

Primary Logo

  • ET PRO
  • Market Data

Market-moving news and views, 24 hours a day >

2018-07-18 00:47:26
0m

July 17 20:00 UTC Released

UST Flows,Incl.Swaps

Actual

31.2 Bln USD

Forecast

Previous

July 17 20:00 UTC Released

USOverall Net Capital Flows

Actual

69.9 Bln USD

Forecast

Previous

January 31 00:00 UTC 241978241978m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 31 00:00 UTC 241978241978m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 22 19:00 UTC 253798253798m

ARTrade Balance

Actual

Forecast

Previous

-1541 %

January 31 00:00 UTC 241978241978m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 22 19:00 UTC 253798253798m

ARTrade Balance

Actual

Forecast

Previous

-1541 %

January 31 00:00 UTC 241978241978m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 31 00:00 UTC 241978241978m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

January 31 00:00 UTC 241978241978m

ARAnnual Primary Balance*

Actual

Forecast

2016 bln ARS

Previous

Bln AR bln ARS

Close

Welcome to EconoTimes

Sign up for daily updates for the most important
stories unfolding in the global economy.